EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 is Imminent

 EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 is Imminent

EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 in Coming Days

Shots:

  • EMA’s head Guido Rasi stated that an initial authorization could be granted to the Gilead’s remdesivir as a potential treatment for COVID-19. The conditional MAA is expected to be issued in coming days
  • Earlier, the EMA has recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorized
  • Additionally, Guido Rasi stated that other possible treatments that may be available fast are mAbs, that can neutralize the SARS-CoV-2

Click here ­to­ read full press release/ article | Ref: Reuters | Image: Twitter

Related News: EMA’s CHMP Recommends Compassionate Use of Gilead’s Remdesivir for COVID-19

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post